Mavacamten

CHEMBL4297517 Phase 4 Aprobado Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

273.3 g/mol

LogP

2.1

Phase

4

A selective cardiac myosin inhibitor used to treat symptomatic obstructive hypertrophic cardiomyopathy (HCM) by reducing the excessive heart muscle contraction that causes obstruction and symptoms. It is the first medication specifically designed to target the underlying mechanism of this inherited heart condition.

Peso molecular

273,3300 g/mol

LogP

2,10

TPSA

61,40 Å²

Regla de cinco de Lipinski

Cumple

Áreas terapéuticas

Insuficiencia cardíaca

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Estructura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O

InChI

InChI=1S/C15H19N3O2/c1-10(2)18-14(19)9-13(17-15(18)20)16-11(3)12-7-5-4-6-8-12/h4-11,16H,1-3H3,(H,17,20)/t11-/m0/s1

Molecular Formula

C15H19N3O2

HBD / HBA

2 / 3

Enlaces Rotables

4

Átomos Pesados

20

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

A selective cardiac myosin inhibitor used to treat symptomatic obstructive hypertrophic cardiomyopathy (HCM) by reducing the excessive heart muscle contraction that causes obstruction and symptoms. It is the first medication specifically designed to target the underlying mechanism of this inherited heart condition.

Yes, Mavacamten is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297517. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 117761397. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

¿Busca información accesible para el paciente?

Mavacamten en PillFYI

Estructura

Datos Rápidos

Fórmula: C15H19N3O2
Sinónimos: 1

Enlaces externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.